Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANIK Stock Forecast 2026-2027
$9.54
Current Price
$137.58M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ANIK Price Targets
+67.7%
To High Target of $16.00
+67.7%
To Median Target of $16.00
+67.7%
To Low Target of $16.00
ANIK Price Momentum
-0.1%
1 Week Change
-0.3%
1 Month Change
-40.4%
1 Year Change
-0.7%
Year-to-Date Change
-48.1%
From 52W High of $18.37
+21.2%
From 52W Low of $7.87
📊 TOP ANALYST CALLS
Did ANIK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Anika is one of their latest high-conviction picks.
Latest ANIK Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ANIK has a bullish consensus with a median price target of $16.00 (ranging from $16.00 to $16.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $9.54, the median forecast implies a 67.7% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Petusky at Barrington Research, projecting a 67.7% upside. Conversely, the most conservative target is provided by Michael Petusky at Barrington Research, suggesting a 67.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANIK Analyst Ratings
2
Buy
0
Hold
0
Sell
ANIK Price Target Range
Low
$16.00
Average
$16.00
High
$16.00
Current: $9.54
Latest ANIK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANIK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | Barrington Research | Michael Petusky | Outperform | Maintains | $16.00 |
| Nov 6, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $16.00 |
| Sep 23, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $15.00 |
| Jul 31, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $15.00 |
| May 12, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $19.00 |
| Mar 13, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $20.00 |
| Nov 1, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $25.00 |
| Oct 22, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $37.00 |
| Aug 9, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $37.00 |
| May 29, 2024 | Stephens & Co. | George Sellers | Equal-Weight | Reiterates | $24.00 |
| May 9, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $37.00 |
| Mar 14, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $37.00 |
| Mar 14, 2024 | Stephens & Co. | George Sellers | Equal-Weight | Reiterates | $22.00 |
| Jan 3, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $29.00 |
| Nov 3, 2023 | Barrington Research | Michael Petusky | Outperform | Maintains | $28.00 |
| Aug 14, 2023 | Barrington Research | Michael Petusky | Outperform | Upgrade | $24.00 |
| Aug 10, 2023 | Stephens & Co. | George Sellers | Equal-Weight | Maintains | $23.00 |
| May 31, 2023 | Stephens & Co. | George Sellers | Equal-Weight | Reiterates | $28.00 |
| Apr 14, 2023 | Stephens & Co. | George Sellers | Equal-Weight | Reiterates | $28.00 |
| Mar 7, 2023 | Barrington Research | Michael Petusky | Market Perform | Downgrade | $N/A |
Anika Therapeutics Inc. (ANIK) Competitors
The following stocks are similar to Anika based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Anika Therapeutics Inc. (ANIK) Financial Data
Anika Therapeutics Inc. has a market capitalization of $137.58M with a P/E ratio of -2.5x. The company generates $112.81M in trailing twelve-month revenue with a -29.3% profit margin.
Revenue growth is -5.9% quarter-over-quarter, while maintaining an operating margin of -11.6% and return on equity of -8.7%.
Valuation Metrics
Market Cap
$137.58M
Enterprise Value
$102.22M
P/E Ratio
-2.5x
PEG Ratio
0.0x
Price/Sales
1.2x
Growth & Margins
Revenue Growth (YoY)
-5.9%
Gross Margin
+56.0%
Operating Margin
-11.6%
Net Margin
-29.3%
EPS Growth
-28.2%
Financial Health
Cash/Price Ratio
+42.1%
Current Ratio
5.3x
Debt/Equity
16.7x
ROE
-8.7%
ROA
-3.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Anika Therapeutics Inc. (ANIK) Business Model
About Anika Therapeutics Inc.
What They Do
Develops therapeutic products for tissue repair.
Business Model
Anika Therapeutics generates revenue by developing, manufacturing, and selling biotechnology and medical devices focused on musculoskeletal conditions, particularly through viscosupplementation products for osteoarthritis pain management and regenerative medicine solutions. The company targets orthopedic care, providing innovative treatments that enhance recovery and quality of life for patients.
Additional Information
Anika Therapeutics is committed to research and development, continuously seeking to innovate and expand its product offerings. Its efforts in advancing global healthcare solutions include collaborations across various medical disciplines, highlighting its role in improving patient outcomes worldwide.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
288
CEO
Dr. Cheryl Renee Blanchard Ph.D.
Country
United States
IPO Year
1993
Website
www.anika.comAnika Therapeutics Inc. (ANIK) Latest News & Analysis
Latest News
Quick Summary
Kirby McInerney LLP is investigating Anika Therapeutics, Inc. (NASDAQ:ANIK) for potential violations of federal securities laws related to its senior management and business practices.
Why It Matters
The investigation into Anika Therapeutics for potential securities violations raises concerns about the company's governance and could impact investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Kirby McInerney LLP is investigating Anika Therapeutics for potential violations of federal securities laws by the company and its management.
Why It Matters
Potential legal issues for Anika Therapeutics could lead to financial penalties or reputational damage, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Anika Therapeutics, Inc. (ANIK) will hold its Q3 2025 earnings call on November 5, 2025, at 8:30 AM EST, featuring key executives including CEO Cheryl Blanchard and CFO Stephen Griffin.
Why It Matters
Anika Therapeutics' Q3 earnings call signals key financial insights and strategic updates, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Anika Reports Third Quarter 2025 Financial Results
2 months ago
Quick Summary
Anika Therapeutics reported a 22% increase in Commercial Channel revenue, driven by strong growth in its Integrity™ Implant System and Hyalofast®. The company reaffirmed its Fiscal 2025 guidance and initiated a $15 million share repurchase.
Why It Matters
Strong revenue growth and product milestones indicate robust demand for Anika Therapeutics’ offerings, reinforcing confidence in future performance and value, especially with share buybacks underway.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Anika Therapeutics (ANIK) reported Q3 earnings of $0.04 per share, surpassing the Zacks estimate of $0.02, compared to a loss of $0.25 per share in the same quarter last year.
Why It Matters
Anika Therapeutics' earnings beat expectations and show significant year-over-year improvement, indicating strong operational recovery and potential for future growth, which can boost investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Anika Therapeutics (NASDAQ: ANIK) will release Q3 2025 financial results on November 5, 2025, before market open, with a conference call at 8:30 a.m. ET to discuss the results.
Why It Matters
Anika Therapeutics' upcoming financial results and conference call could impact stock performance, reflecting company health and future strategies, influencing investor sentiment and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ANIK Stock
What is Anika Therapeutics Inc.'s (ANIK) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Anika Therapeutics Inc. (ANIK) has a median price target of $16.00. The highest price target is $16.00 and the lowest is $16.00.
Is ANIK stock a good investment in 2026?
According to current analyst ratings, ANIK has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.54. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANIK stock?
Wall Street analysts predict ANIK stock could reach $16.00 in the next 12 months. This represents a 67.7% increase from the current price of $9.54. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Anika Therapeutics Inc.'s business model?
Anika Therapeutics generates revenue by developing, manufacturing, and selling biotechnology and medical devices focused on musculoskeletal conditions, particularly through viscosupplementation products for osteoarthritis pain management and regenerative medicine solutions. The company targets orthopedic care, providing innovative treatments that enhance recovery and quality of life for patients.
What is the highest forecasted price for ANIK Anika Therapeutics Inc.?
The highest price target for ANIK is $16.00 from Michael Petusky at Barrington Research, which represents a 67.7% increase from the current price of $9.54.
What is the lowest forecasted price for ANIK Anika Therapeutics Inc.?
The lowest price target for ANIK is $16.00 from Michael Petusky at Barrington Research, which represents a 67.7% increase from the current price of $9.54.
What is the overall ANIK consensus from analysts for Anika Therapeutics Inc.?
The overall analyst consensus for ANIK is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are ANIK stock price projections?
Stock price projections, including those for Anika Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 5:52 AM UTC